Orientador: Jaime Olbrich Neto / Resumo: Os cabelos são um importante componente de identidade social e sedução, favorece o mercado de cosméticos, notadamente o capilar, que busca inovações e novidades destinadas a obter um resultado desejado. Mulheres e homens dão importância para a saúde e aparência dos mesmos, empenhando cuidados que vão além dos habituais de higiene. A procura pelo cabelo ideal expõe a riscos de doenças, tanto os profissionais dos salões de beleza e como seus clientes. São doenças ocupacionais, em muitos casos, negligenciadas. Entre estes riscos encontra-se a dermatite de contato. No Brasil, a chamada escova progressiva é a mais conhecida e utilizada para alisamento. Neste processo o uso de formaldeído (FA) em concentrações não permitidas tem sido prática comum, expondo cabeleireiros e clientes a risco de doenças relacionadas ao contato com FA. O FA é permitido na concentração de até 0,2% como conservante de produtos. O presente estudo objetivou avaliar indivíduos expostos ao FA ao realizarem alisamento capilar, se estavam sensibilizados ao FA. Para identificar FA em produtos de alisamento capilar, usado pelos cabeleireiros participantes desta pesquisa, utilizou-se um kit comercialmente disponível. Foram incluídos profissionais expostos ao FA, clientes (esporadicamente expostos) e indivíduos nunca expostos. Foram realizados patch teste com a bateria brasileira para dermatite de contato, e um participante apresentou teste cutâneo positivo para formol, onze para bicromato de potássio e oito para s... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Hair is an important component of social identity and seduction, it favors the cosmetics market, notably the capillary, which seeks innovations and novelties designed to obtain a desired result. Women and men give importance to their health and appearance, engaging in care that goes beyond the usual hygiene. The search for the ideal hair exposes the risks of diseases, both the professionals of the beauty salons and their clients. Occupational diseases that are, in many cases, neglected. Contact dermatites is one of the risks. In Brazil, the so-called brazilian hair straightening is the preferred for straightening. In this process, the use of formaldehyde (FA) in unallowed concentrations has been common practice, exposing hairdressers and clients to the risk of diseases related to contact with FA. At a concentration of up to 0.2%, as a p preservative, FA is permitted. The present study aimed to evaluate individuals exposed to FA when performing hair straightening, and if they were sensitized to FA. To identify FA in hair straightening products, used by hairdressers participating in this research, a commercially available kit was used. Professionals exposed to the FA, clients (sporadically exposed) and individuals never exposed were included. Patch tests were performed with the Brazilian battery for contact dermatitis, and one participant presented a positive skin test for formaldehyde, eleven for potassium bichromate and eight for nickel sulfate. Clinical symptoms were more se... (Complete abstract click electronic access below) / Mestre

Bakgrund: Atopisk dermatit (AD) är en vanlig kronisk inflammatorisk hudsjukdom som kännetecknas av eksematösa vätskande sår och intensiv klåda. AD är dels en T-hjälparcell (TH) - 2 driven sjukdom vilket innefattar den akuta fasen av sjukdomen där TH2-cellerna blir aktiverade och börjar producera cytokinerna interleuin (IL)-4, IL-5 samt IL13. I den kroniska fasen ses i stället en dominans av TH1-celler som i stället främst uttrycker cytokiner som γ-interferon (IFN- γ) och IL-12 vilket bidrar till en kronisk inflammation. Personer som har milda symtom kan ofta kontrollera sjukdomen med enbart topikala medel. För personer som har svårare symtom kan fototerapi eller systemisk behandling behövas. Abrocitinib/Upadacitinib är selektiva janus-kinas (JAK)1-hämmare och hämmar signalvägen som annars resulterar i produktion av proinflammatoriska cytokiner och tillväxtfaktorer. Behandlingen resulterar i minskad inflammation i huden. Dupilumab är en monoklonal antikropp som hämmar IL-4 och IL-13 vilket också resulterar i minskad inflammation.  Syfte: Syftet medstudien var att kritiskt granska utfallet i publicerade studier vad gäller abrocitinib/upadacatinib och dubilumab samt att jämföra skillnaden i effekt och säkerhet för att bedöma hur stor betydelse den nya behandlingen kan ha för patienter med måttlig till svår AD.  Metod: Arbetet är en litteraturstudie som är baserad på sex vetenskapliga artiklar som är hämtade via databasen PubMed. Studier inkluderades som innefattade monoterapi samt om dess primära utfallsvariabel var EASI75 eller IGA.  Resultat: Två studier uppvisade signifikant förbättrad effekt av abrocitinib i två styrkor mot placebo. Studien som jämförde upadacitinib i två styrkor mot placebo visade på signifikant förbättrad effekt mot placebo. Jämförelse av 300 mg dupilumab mot placebo uppvisade också signifikant förbättrad effekt. I en studie där 30 mg upadacitinib jämfördes mot 300 mg dupilumab visade upadacitinib på signifikant förbättrad effekt mot dupilumab. I en annan studie där 100 mg respektive 200 mg abrocitinib jämfördes mot dupilumab och placebo uppvisade abrocitinib förbättrad effekt mot både dupilumad och placebo, dock ej statistiskt signifikant. Biverkningar rapporterades i högre grad för 200 mg-gruppen samt 30 mg upadacitinib-gruppen jämfört med dupilumab. Samtliga studier är sponsrade av läkemedelsföretag som har utvecklat respektive studieläkemedel vilket kan öka risk för bias då företagen vill att deras produkt ska visa på så god effekt som möjligt.  Slutsats: Abrocitinib/upadacitinib anses vara bra behandlingsalternativ för patienter med måttlig till svår AD då det visar på god effekt jämfört med placebo. Dupilumab visar likaså på bra effekt jämfört med placebo. Jämförande studier mellan abrocitinib/upadacitinib mot dupilumab visar på bättre effekt av andelen patienter som uppnådde det primära effektmåttet. Dock är resultatet mellan studieläkemedlena inte markant överlägset någon annan även om abrocitinib/upadacitinib visar på bättre effekt än dupilumab i båda jämförande studierna där resultatet i studie är statistiskt signifikant. / Atopic dermatitis (AD) is a common well-known chronic inflammatory skin disease characterized by eczematous exuding wounds and intense itching. AD is partly a disease driven by the t-helper (TH) 2-cells and involves activation of the acute phase of the disease that starts to produce cytokines interleukin (IL) – 4, IL-5 and IL-13. TH1-cells stands mainly for the expression of cytokines as g-interferon (IFN-g) and IL-12 which contribute to the chronic inflammation. For people with mild symptoms it is usually enough to treat with topical steroids but people who suffer from more severe symptoms, systemic treatment may be needed. Abrocitinib/Upadacitinib is a new selective JAK-1 inhibitor that inhibit the pathway which otherwise results in production of proinflammatory cytokines and growth factors. That results in less inflammation in skin. Dupilumab, that is an inhibitor of IL-4 and IL-13 also results in less inflammation in skin, has been the only approved biological treatment against moderate to severe AD until abrocitinib and upadacitinb was discovered. There is a need of more alternative and safe systemic therapies. This study aims to critically examine the results in different published articles to criticize which treatment of the comparable drugs is the best for patients considering both effect and safety with patients suffering from moderate to severe AD.  This study is based on six scientific articles from PubMed. Studies included if the patients was treated with monotherapy and if the primary outcome was EASI75 and IGA. Two studies presented significantly improved effect of abrocitinib in two different strengths against placebo. One study that compared upadacitinib in two strengths against placebo also showed on significantly improved effect. Comparison of dupilumab 300 mg against placebo showed on significantly improved effect. One study that compared 30 mg upadacitinib against 300 mg dupilumab showed significantly improved effect against dupilumab. The last study that compared 100 mg respectively 200 mg abrocitinib against 300 mg dupilumab showed improved effect of abrocitinib against dupilumab, although it was not significant. Side effects were reported most frequently in the 200 mg abrocitinib study group and also in the 30 mg upadacitinib study group comparable to dupilumab. All of the studies are funded by pharmaceutical companies that also have developed the different study-drugs that is investigated which may increase the risk of bias.   In summary, abrocitinib/upadacitinib is considered a good treatment option for patients suffering from moderate to severe AD comparable with placebo. Treatment with dupilumab also shows on a good treatment comparable to placebo. Studies comparing abrocitinib/upadacitinib with dupilumab shows on more effect of the amount of patients that achieved primary outcome. However, the results between the drugs are not remarkable superior to any other even though abrocitinib/upadacitinib shows on a better effect than dupilumab in both comparative studies.

Este trabajo de investigación pretende, a través de una estrategia integrada y considerando el escenario de uso de calzado de cuero, evaluar el potencial sensibilizante del Cr(VI) mediante ensayos in vitro e in vivo a concentraciones por debajo de la restricción existente de obligado cumplimiento y determinar los niveles de exposición reales de Cr(VI), utilizando metodología de nuevo desarrollo, simulando las condiciones generadas en el microclima pie-zapato.

Digital dermatitis is a top cause of lameness in dairy cattle that results in ulcerative lesions on the feet. Topical salicylic acid has been shown to provide similar efficacy to the antibiotic drugs used previously, but there is no milk withholding time established in the United States. The objective of this study was to provide data in order to establish this withholding period. A secondary objective was to evaluate outcomes among treatments. Treatment groups were topical applications of the following drugs: salicylic acid paste, salicylic acid powder, and tetracycline. The lesions were scored at day 0, day 7, and day 28 post-treatment. Milk samples were collected the day before treatment, 4 hours, 8 hours, 24 hours, 36 hours, and 48 hours post-treatment. Results indicated that most cows did not show detectable levels of salicylic acid after 24 hours.

No description available.

京都大学 / 新制・論文博士 / 博士(医学) / 乙第13454号 / 論医博第2247号 / 新制||医||1055(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 竹内 理, 教授 杉田 昌彦, 教授 生田 宏一 / 学位規則第4条第2項該当 / Doctor of Medical Science / Kyoto University / DFAM

No description available.

No description available.

No description available.

No / IL-33 is a member of the IL-1 family of cytokines that is constitutively expressed in healthy skin and was found to be increased in the skin of patients with atopic dermatitis (AD). Because it can be released after tissue damage or physical stress including scratching of the skin,1 it has been classified as an alarmin concerned with alerting the immune system.2 It enhances TH2 responses by inducing IL-5 and IL-13 as well as TH1 responses via upregulation of IFN-γ. Keratinocytes are known producer cells of IL-33 and also express the receptor complex consisting of ST2 and IL-1RAcP on their surface. The aim of this study was to investigate the effect of IL-33 on keratinocytes, skin biopsies, and living skin equivalents with regard to the regulation of the skin barrier molecule filaggrin (FLG).